MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Emerging Growth Conference

Rhea-AI Summary

MetaVia (Nasdaq: MTVA) will present an update on its novel obesity and metabolic therapy pipeline at the Emerging Growth Conference on Wednesday, February 25, 2026 at 10:15 am ET. Management will include CEO Hyung Heon Kim and CFO Marshall H. Woodworth and will take audience questions after the talk.

Investors can register for the virtual conference, submit questions in advance to questions@emerginggrowth.com, or schedule one-on-one meetings via mmiller@rxir.com.

News Market Reaction – MTVA

-6.10%

11 alerts

-6.10% News Effect

+10.3% Peak Tracked

-7.7% Trough Tracked

-$358K Valuation Impact

$6M Market Cap

0.3x Rel. Volume

On the day this news was published, MTVA declined 6.10%, reflecting a notable negative market reaction. Argus tracked a peak move of +10.3% during that session. Argus tracked a trough of -7.7% from its starting point during tracking. Our momentum scanner triggered 11 alerts that day, indicating notable trading interest and price volatility. This price movement removed approximately $358K from the company's valuation, bringing the market cap to $6M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Conference date: February 25, 2026 Current price: $1.64 52-week range: $1.54–$23.10 +2 more

5 metrics

Conference date February 25, 2026 Emerging Growth Conference presentation timing

Current price $1.64 Pre-news trading level vs 52-week range

52-week range $1.54–$23.10 Low and high over past 52 weeks

Volume spike 5.66x average Today’s volume vs 20-day average

Market cap $5,436,869 Equity value before conference update

Market Reality Check

Price: $1.59 Vol: Volume 2,400,504 is 5.66x...

high vol

$1.59 Last Close

Volume Volume 2,400,504 is 5.66x the 20-day average of 423,981, indicating elevated activity ahead of the conference update. high

Technical Shares at $1.64 are trading below the 200-day MA of $7.90 and sit 92.9% under the 52-week high of $23.10, though still above the $1.54 52-week low.

Peers on Argus

Argus momentum data shows mixed peer moves: two biotech peers up (median about 8...

2 Up 2 Down

Argus momentum data shows mixed peer moves: two biotech peers up (median about 8%) and two down, while MTVA is down 1.2%. This split suggests company-specific trading rather than a clean sector-wide rotation.

Historical Context

5 past events · Latest: Feb 13 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 13	IP protection update	Positive	-1.2%	Announced 39-patent portfolio for DA-1726 with protection into 2041.
Feb 04	AI collaboration data	Positive	-2.1%	Reported positive AI-modeling results confirming targets for vanoglipel.
Jan 16	Equity offering	Negative	-3.5%	Closed ~$9.3M underwritten public offering with Series C and D warrants.
Jan 05	Phase 1b results	Positive	-8.7%	Reported statistically significant Phase 1b DA-1726 metabolic and weight-loss data.
Dec 29	Conference participation	Neutral	-2.1%	Announced participation and sponsorship of the 10th Annual MASH-TAG 2026 conference.

Pattern Detected

Recent history shows multiple positive clinical and IP updates followed by negative next-day moves, while the January offering aligned with a further price decline.

Recent Company History

Over the past few months, MetaVia announced positive Phase 1b data for DA-1726, strong Phase 2a results for vanoglipel, and a robust patent estate for DA-1726 extending to 2041. It also completed an underwritten public offering of about $9.3 million and participated in sector conferences. Despite favorable clinical and IP news, 24-hour reactions after these events were negative, framing today’s conference-focused announcement within a pattern of pressure around news flow.

Market Pulse Summary

The stock moved -6.1% in the session following this news. A negative reaction despite a routine conf...

Analysis

The stock moved -6.1% in the session following this news. A negative reaction despite a routine conference update fits a pattern where MetaVia’s positive news, including DA-1726 and vanoglipel data, was followed by 24-hour declines of up to 8.68%. Shares sat at $1.64, far below the $23.10 52-week high and close to the $1.54 low, and traded on 5.66x normal volume, suggesting sentiment and prior dilution from the January offering could continue to weigh on the stock around news events.

Key Terms

obesity, metabolic, cardiometabolic

3 terms

obesity medical

"company's pipeline of novel obesity and metabolic therapies at the Emerging Growth"

A chronic medical condition in which a person carries excess body fat that can impair health, commonly assessed by standard measures such as body-mass index or waist circumference. For investors, obesity matters because it drives demand for medical treatments, weight-management products, health services and insurance payouts, and can affect workforce productivity and public health policy — similar to how a fleet with heavier loads needs more fuel and maintenance, creating ongoing market opportunities and costs.

metabolic medical

"pipeline of novel obesity and metabolic therapies at the Emerging Growth Conference"

Metabolic describes the chemical processes in living organisms that turn food and nutrients into energy, building materials and waste — essentially the body’s internal fuel-and-repair system. For investors, the term signals drugs, tests or devices aimed at conditions tied to those processes (such as diabetes or obesity); like improving an engine’s efficiency, successful metabolic therapies can expand a company’s market by treating widespread, chronic health problems.

cardiometabolic medical

"clinical-stage biotechnology company focused on transforming cardiometabolic diseases"

Cardiometabolic describes health conditions that affect the heart and the body’s metabolism—most commonly heart disease, high blood pressure, type 2 diabetes and obesity—that often occur together and share common causes. Investors care because these linked conditions drive large, predictable demand for drugs, medical devices and long-term care, and changes in treatment options, guidelines or costs can materially affect healthcare company revenues and government spending much like a problem in an engine and its fuel system impacts the whole vehicle.

AI-generated analysis. Not financial advice.

CAMBRIDGE, Mass., Feb. 17, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that Hyung Heon Kim, President and Chief Executive Officer and Marshall H. Woodworth, Chief Financial Officer, will present a update highlighting the company's pipeline of novel obesity and metabolic therapies at the Emerging Growth Conference on Wednesday, February 25, 2026 at 10:15 am ET.

After the presentation, MetaVia management will open the floor for questions. Please submit your questions in advance to questions@emerginggrowth.com, or ask your questions during the event.

Please register using this link to attend the virtual conference and receive any updates that are released. To schedule a meeting with management outside of the conference, please contact Michael Miller at mmiller@rxir.com.

About MetaVia
MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. The company is currently developing DA-1726 for the treatment of obesity, and is developing vanoglipel (DA-1241) for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists. In a Phase 1 multiple ascending dose (MAD) trial in obesity, DA-1726 demonstrated best-in-class potential for weight loss, glucose control, and waist reduction. Vanoglipel is a novel G-protein-coupled receptor 119 (GPR119) agonist that promotes the release of key gut peptides GLP-1, GIP, and PYY. In pre-clinical studies, vanoglipel demonstrated a positive effect on liver inflammation, lipid metabolism, weight loss, and glucose metabolism, reducing hepatic steatosis, hepatic inflammation, and liver fibrosis, while also improving glucose control. In a Phase 2a clinical study, vanoglipel demonstrated direct hepatic action in addition to its glucose lowering effects.

For more information, please visit www.metaviatx.com.

Contacts:

MetaVia
Marshall H. Woodworth
Chief Financial Officer
+1-857-299-1033
marshall.woodworth@metaviatx.com

Rx Communications Group
Michael Miller
+1-917-633-6086
mmiller@rxir.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/metavia-to-highlight-novel-obesity-and-metabolic-therapies-at-upcoming-emerging-growth-conference-302688425.html

SOURCE MetaVia Inc.

FAQ

When will MetaVia (MTVA) present at the Emerging Growth Conference?

MetaVia will present on Wednesday, February 25, 2026 at 10:15 am ET, giving a pipeline update. According to the company, CEO Hyung Heon Kim and CFO Marshall H. Woodworth will lead the presentation and take questions from attendees after the session.

How can investors register to attend MetaVia (MTVA) at the February 25, 2026 conference?

Investors can register using the event registration link provided by the conference to attend virtually. According to the company, registration grants access to the live presentation, any released updates, and follow-up materials distributed by the conference organizers.

Who from MetaVia (MTVA) will present the pipeline update on February 25, 2026?

The presentation will be delivered by CEO Hyung Heon Kim and CFO Marshall H. Woodworth, focusing on obesity and metabolic therapies. According to the company, both executives will provide program highlights and then open the floor for audience questions.

Can shareholders ask questions during MetaVia's (MTVA) Emerging Growth Conference presentation?

Yes, MetaVia management will take questions after the presentation and encourages advance submissions. According to the company, submit questions to questions@emerginggrowth.com or ask live during the virtual session for management to address.

How can investors schedule a one-on-one meeting with MetaVia (MTVA) management around the conference?

To schedule a meeting outside the conference, contact Michael Miller at mmiller@rxir.com to arrange a one-on-one session. According to the company, this facilitates follow-up discussions beyond the public presentation and Q&A.